Endometrial Cancer Clinical Trials

Mobile : University of South Alabama / Mitchell Cancer Institute Univ South Alabama

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Phoenix : St. Joseph's Hospital and Medical Center

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

Concord : John Muir Clinical Research Center

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

Fullerton : St. Jude Heritage Medical Group St Jude

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Los Angeles : University of California at Los Angeles UCLA 3

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Los Angeles : USC/Kenneth Norris Comprehensive Cancer Center USC 2

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Los Angeles : Cedars Sinai Medical Center TKI258A2211 (SC)

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

View More »

Santa Maria : Central Coast Medical Oncology Corporation

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Greenwood Village : Rocky Mountain Cancer Centers Dept. of Rocky Mountain Cancer

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Farmington : University of Connecticut Health Center

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

New Haven : Smilow Cancer Hospital at Yale New Haven

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

New Haven : Yale University School of Medicine

Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers

Orlando : Florida Hospital Cancer Institute FL Hosp

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

Indianapolis : Indiana University Health Goshen Center for Cancer IU Simon Cancer

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Iowa City : University of Iowa Hospitals & Clinics SC

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Baltimore : Greater Baltimore Medical Center

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

Detroit :

Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors

Lincoln : Southeast Nebraska Oncology Cancer Center

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Neptune : Jersey Shore University Medical Center

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

Bronx : Montefiore Medical Center

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

New York :

Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors

Asheville : Hope A Woman's Cancer Center

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Chapel Hill : University of North Carolina

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

Durham : Duke University Medical Center Duke3

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Durham : Duke University School of Medicine

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

Hilliard : The Ohio State University

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

Greenville : Cancer Centers of the Carolinas SC-1

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Memphis : The West Clinic SC

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Nashville : Vanderbilt University Medical Center SC-2

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Nashville :

Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors

Bedford : Texas Oncology, P.A. Tex Onc (3)

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Bedford : Texas Oncology, P.A. Austin

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Fort Worth : Texas Oncology, P.A. SC

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Houston : UT MD Anderson Cancer Center

Chemoradiation-Induced Nausea and Emesis: Quality of Life

San Antonio : South Texas Oncology and Hematology, PA South Tex Onc

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Additional Locations : Virginia Oncology Associates VOA - Lake Wright

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Charlottesville : University of Virginia

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

Spokane : Cancer Care Northwest SC

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Graz : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Innsbruck : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

St Poelten : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Vöcklabruck : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Wels : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

View More »

Wien : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Aalst : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bonheiden : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Brasschaat : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Brugge : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Eupen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

View More »

Gilly : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Mechelen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Namur : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Oostende : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Sint-Niklaas : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Verviers : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Belo Horizonte : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Porto Alegre : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Ribeirao Preto : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Aix en Provence : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Aix en Provence cedex 01 : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Amiens : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bayonne : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Besançon Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

View More »

Bordeaux : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Boulogne sur Mer Cédex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bourg en Bresse : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Brive la Gaillarde : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Clermont Ferrand : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Colmar Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Dijon : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

La Seyne Sur Mer : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Le Mans Cedex 9 : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Longjumeau cedex 1 : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Marseille : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Mont de Marsan : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Nancy : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Périgueux cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Paris Cedex 20 : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Pontoise Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Pringy Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Reims : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Reims Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Rennes : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Rouen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Saint Grégoire cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Saint Quentin : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Soissons Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Soyaux : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Strasbourg : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Vichy cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Villefranche Sur Saone Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Villejuif Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Augsburg : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Berlin : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bremerhaven : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Goslar : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Halle/Saale : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

View More »

Köln : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Kassel : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Mannheim : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Neunkirchen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Stralsund : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Würselen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Athens : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Chania : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Marousi : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Papagou : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Thessaloniki : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Candiolo : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Cefalù PA : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Genova : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Milano : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Monza : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

View More »

Napoli : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Padova : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Pisa : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Roma : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Roma : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Torino : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Seoul : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Seoul : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Seoul : Asan Medical Center

Efficacy Study of Chemotherapy Followed by Radiation Therapy to Treat Endometrial Cancer

Seoul : Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center

Efficacy Study of FloSeal for Prevention of Lymphocele After Lymphadenectomy for Gynecologic Cancer

Amstelveen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Amsterdam : Research Site

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Dordrecht : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Enschede : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Leiderdorp : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

View More »

Purmerend : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Roosendaal : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Vlissingen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Zutphen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Grafton, Auckland : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Bialystok : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Gdansk : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Koszalin : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Krakow : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Lubin : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

View More »

Olsztyn : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Poznan : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Walbrzych : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Wroclaw : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Alba Iulia : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Baia-Mare : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Brasov : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bucharest : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bucuresti : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

View More »

Cluj-Napoca : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Oradea : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Ramnicu Valcea : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Targu Mures : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Timisoara : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Barcelona : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Cordoba : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Majadanonda : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Málaga : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Murcia : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

View More »

Oviedo : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Sabadell : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Glasgow : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Leeds : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

London : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Manchester : Research Site

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Nottingham : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

View More »

Sutton : Research Site

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules